Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

José Miguel Cisneros, director of the infectious disease department at Seville’s Virgen del Rocío Hospital, on Tuesday announced the first casualty since the outbreak was declared on Aug. 15. Authorities have closed the pork meat supplier’s plant and recalled all of its products. Cisneros said roughly half of the 114 people affected by the bacteria remain hospitalized. Health Minister María Luisa Carcedo said an investigation is looking into how the meat evaded what she called “strict food safety controls.” Listeria is a bacteria that usually causes mild illness in healthy people but can be dangerous to pregnant women and those with weakened immune systems.
Woman dies in Spain as listeria-in-pork outbreak sickens 114.

Amid warnings from public health officials that a 2020 outbreak of a new coronavirus could soon become a pandemic involving the U.S., alarmed readers asked Snopes to verify a rumor that U.S. President Donald Trump had “fired the entire pandemic response team two years ago and then didn’t replace them.” The claim came from a series of tweets posted by Judd Legum, who runs Popular Information, a newsletter he describes as being about “politics and power.” Legum’s commentary was representative of sharp criticism from Democratic legislators (and some Republicans) that the Trump administration had ill-prepared the country for a pandemic even as one was looming on the horizon. Legum outlined a series of cost-cutting decisions made by the Trump administration in preceding years that had gutted the nation’s infectious disease defense infrastructure. The “pandemic response team” firing claim referred to news accounts from Spring 2018 reporting that White House officials tasked with directing a national response to a pandemic had been ousted. Rear Adm. Timothy Ziemer abruptly departed from his post leading the global health security team on the National Security Council in May 2018 amid a reorganization of the council by then-National Security Advisor John Bolton, and Ziemer’s team was disbanded. Tom Bossert, whom the Washington Post reported “had called for a comprehensive biodefense strategy against pandemics and biological attacks,” had been fired one month prior. It’s thus true that the Trump administration axed the executive branch team responsible for coordinating a response to a pandemic and did not replace it, eliminating Ziemer’s position and reassigning others, although Bolton was the executive at the top of the National Security Council chain of command at the time. Legum stated in a follow-up tweet that “Trump also cut funding for the CDC, forcing the CDC to cancel its efforts to help countries prevent infectious-disease threats from becoming epidemics in 39 of 49 countries in 2018. Among the countries abandoned? China.” That was partly true, according to 2018 news reports stating that funding for the CDC’s global disease outbreak prevention efforts had been reduced by 80%, including funding for the agency’s efforts in China. But that was the result of the anticipated depletion of previously allotted funding, not a direct cut by the Trump administration. And as the CDC told FactCheck.org, the cuts were ultimately avoided because Congress provided other funding.
The Trump administration fired the U.S. pandemic response team in 2018 to cut costs.

Cost of treatment not mentioned. 5-year estimated outcomes were given after only 2 years of data. No quantitative data on safety presented. Absolute numbers provided. Limited long term data and small absolute benefit are key issues here. Does not mention the increase in cholesterol and cardiovascular disease among the women in the aromatase inhibitor group. Tamoxifen may have a positive, cholesterol-lowering effect, which is also not mentioned. Study design not adequately discussed. It didn’t really describe that some of the data were likely gathered on women with more advanced disease where the benefits would be bigger. Gives estimates of women diagnosed with this type of breast cancer. Perhaps not enough emphasis that this is only for post menopausal women with invasive disease — e.g. last line in story assumes all estrogen receptor/progesterone receptor positive women are eligible. Journalist notes that the study was funded by Novartis, maker of Femara, and that many of the researchers own stock in this company or in companies for rival drugs. Mentions other adjuvant drug treatment, tamoxifen, as well as some side effects of both of the aromatase inhibitor drugs (Femara and Arimide) studied as well as Tamoxifen. Story about FDA approval for women with early-stage invasive disease. Discusses how drug is already in use for women with advanced breast cancer.

Drug OK’d to Fight Breast Cancer Relapse